•  
Personalize Therapies.
ImmunoMind is an open-source ecosystem for designing personalized immunotherapies and vaccines using systems immunology.
Moonshot startup from UC Berkeley SkyDeck and Next Sequence
Pfizer · Novartis · UCSF · Stanford · MIT · MD Anderson Cancer Center ·
The Johns Hopkins University School of Medicine
and the global community of 60,000 medical scientists and researchers worldwide
From the team behind Immunarch – the gold standard for immunomics data analysis, trusted by:
Focus.
  • Therapy efficacy prediction by deciphering the drug-immune system interactions
  • Patient stratification and monitoring using multi-omics biomarkers
  • Immune cell-based biomarker discovery from single-cell and bulk multi-omics data
Applications.
Select the most effective CAR-T product by comparing cell population characteristics across products.
Early assessment of CAR-T cell populations is critical for improving success in later development stages. With ImmunoMind, you can evaluate CAR-T cells' activation, proliferation, cytotoxicity, senescence, and exhaustion, simultaneously comparing characteristics of several CAR-T products to help companies choose the most effective candidate.
Improve CAR-T product efficacy through exhaustion estimation.
T-cell exhaustion is a dysfunctional state of T-cells arising from excessive antigen stimulation. It is considered to be one of the critical factors at all stages of CAR-T development and manufacturing. ImmunoMind's technologies precisely evaluate CAR-T cell exhaustion, helping companies refine CAR-T products for improved efficacy.
Address the extensive heterogeneity of CAR-T drugs to reduce toxicity.
Heterogeneity subpopulations and CD4+/CD8+ ratio are vital attributes of CAR-T products that should be analyzed to develop effective drugs. By using single-cell technologies, it is now possible to dive into the internal context of CAR-T products while delineating cell subtypes and cell diversity.
Improve the CAR-T manufacturing process using cell differentiation insights.
The predominance of more differentiated cells in the final CAR-T product diminishes efficacy. Identifying various differentiated subpopulations optimizes the CAR-T manufacturing process. ImmunoMind's actionable insights assist in selecting the most effective composition of a CAR-T product and allow manufacturing process modification.
Why partner with us?
Biotech Startups – De-risk
De-risk immunotherapy on the crucial discovery steps by focusing on the most efficient immunotherapy candidates.
Immunotherapy Biopharma – Better Efficacy
Focus on immunotherapy candidates that work and stratify patients for successful clinical trials.
Research Groups – Fuel Discovery
Study immune cell biology and discover new targets and biomarkers for immunotherapies with the AI and bioinformatics capabilities of ImmunoMind.